Extended Half-Life (EHL) Recombinant Factor IX
Treatment used for 1 condition
Total Trials
40
Total Participants
6K
Avg Effectiveness
90%
Avg Safety Score
68%
Conditions Treated
Click on a condition to view detailed treatment information and clinical trial data.